Articles

Results 1 to 5 of 29
Most popular |Most recent


Federal Court of Appeal Offers Further Guidance on Elevated Costs Awards

Canada - October 1 2021 The Federal Court of Appeal has provided further guidance on the circumstances under which litigants may obtain costs awards exceeding those…

Mitchel Fleming, Bruna D.D. Kalinoski.

2021 Canadian Pharma Litigation Mid-Year Recap: Key Takeaways from the Year So Far

Canada - July 7 2021 Despite continued COVID-19 lockdowns and restrictions, 2021 has seen no shortage of Canadian judicial and patent Appeal Board decisions affecting the…

Martin Brandsma, Raffi Dergalstanian.

Federal Court of Appeal Affirms Site-Blocking Order in Teksavvy Case

Canada - June 11 2021 On May 26, 2021, the Federal Court of Appeal released its much awaited decision in Teksavvy Solutions Inc v. Bell Media Inc.1 The Court unanimously…

Raffi Dergalstanian, Bruna D.D. Kalinoski.

Federal Court of Appeal Affirms Minister’s Decision that CSP Eligibility Requires Claim for Active Ingredients and Excludes Formulations Claims

Canada, European Union - May 4 2021 The Federal Court of Appeal (“FCA”) recently released its first decision on a judicial review challenge against the Minister of Health’s (the…

Bruna D.D. Kalinoski.

Nearly 400-Year-Old English Statute of Monopolies Not Applicable to Damage Claim Under Canada’s Patented Drug Regime

Canada - March 24 2021 In 1624, England introduced its Statute of Monopolies1 to limit perceived abuses by the monarch in awarding monopolies over various economic…

Martin Brandsma.